ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock News

NASDAQ:ARQT - US03969K1088 - Common Stock

15.65 USD

-0.18 (-1.14%)

Last: 8/27/2025, 8:00:01 PM

15.6799 USD

+0.03 (+0.19%)

After Hours: 8/27/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ARQT Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Chartmill

News Image

Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Fits the Minervini Trend Template with Strong Growth Momentum

12 hours ago - By: Zacks Investment Research - Mentions: FHTX

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

2 days ago - By: MarketBeat - Mentions: BSX TARS

3 Biotech Catalysts Present Major Opportunity

8 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Present at Upcoming Investor Conferences

13 days ago - By: Zacks Investment Research

Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know

17 days ago - By: Zacks Investment Research - Mentions: THC

Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

19 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

21 days ago - By: The Motley Fool

Arcutis (ARQT) Q2 Revenue Soars 164%

21 days ago - By: Zacks Investment Research - Mentions: RNA

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

21 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

21 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

22 days ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

2 months ago - By: Yahoo Finance - Mentions: VZ AMZN WMT CADE ...

How Cadence Bank, Kimberly-Clark, And Robert Half Can Put Cash In Your Pocket

2 months ago - By: Yahoo Finance - Mentions: UBS KR UNP DE ...

UBS Maintains Neutral on Kroger Ahead of Earnings, Sees Balanced Risk-Reward Outlook

2 months ago - By: Yahoo Finance - Mentions: BLND SNY NVDA TSM ...

Covius Services to Acquire Blend Labs’ (BLND) Title365 Holding Co

2 months ago - By: Yahoo Finance - Mentions: ELV ACGL AGIO AZN ...

Truist Lowers Elevance Health (ELV) to $500, Keeps Buy Rating

2 months ago - By: Yahoo Finance - Mentions: SPRY MEOH GSC KR ...

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

3 months ago - By: Benzinga

Analyst Expectations For Arcutis Biotherapeutics's Future

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

3 months ago - By: Arcutis Biotherapeutics, Inc.

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

3 months ago - By: Arcutis Biotherapeutics, Inc.

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

4 months ago - By: Zacks Investment Research - Mentions: SABS

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)